Relmada Therapeutics (RLMD) seasonality heatmap
Returns across monthly, quarterly, and yearly periods. Cell color encodes signed magnitude; the scale auto-fits each table.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.5% | +28.5% | +52.6% | +8.0% | -4.1% | -7.8% | — | — | — | — | — | — |
| 2025 | -32.9% | -25.5% | +3.8% | +19.4% | +132.6% | -20.0% | +3.7% | +79.9% | +79.5% | +12.4% | +99.6% | +7.1% |
| 2024 | -4.6% | +55.7% | -24.2% | -21.6% | -17.6% | +0.0% | +22.0% | -23.5% | +15.7% | +7.4% | -13.2% | -31.1% |
| 2023 | +15.8% | -10.9% | -37.2% | +11.5% | +12.7% | -13.4% | +6.5% | +29.0% | -11.2% | -0.3% | -17.4% | +66.8% |
| 2022 | -18.4% | +11.4% | +31.7% | -7.0% | -25.1% | +1.1% | +34.7% | +13.9% | +26.9% | -78.4% | -27.5% | -24.8% |
| 2021 | +2.0% | +2.0% | +5.5% | +9.5% | -10.2% | -7.5% | -18.8% | -8.1% | +9.6% | -10.5% | -23.9% | +26.3% |
| 2020 | +13.7% | +10.0% | -30.1% | +23.0% | +14.9% | -7.2% | -18.8% | -1.8% | +5.3% | -17.7% | +14.9% | -9.8% |
| 2019 | +19.6% | -3.6% | +34.0% | +2.1% | +37.9% | -26.0% | +18.9% | +15.9% | +0.5% | +173.2% | +14.8% | +21.3% |
| 2018 | +0.0% | -6.7% | +27.1% | +64.3% | -6.0% | -26.5% | +18.8% | -24.8% | +24.1% | +7.1% | -3.3% | -0.9% |
| 2017 | +10.1% | -32.5% | +11.1% | +15.6% | -3.8% | -18.0% | +0.0% | -7.3% | +25.0% | -15.5% | -6.5% | +0.0% |
| 2016 | -44.5% | +8.1% | +13.3% | +89.0% | -5.8% | -24.8% | -15.4% | -31.2% | +11.3% | -22.0% | -13.9% | +10.1% |
| 2015 | -9.7% | -2.1% | +7.7% | -29.5% | -4.8% | +2.5% | -36.0% | -23.1% | -2.0% | -25.5% | -19.2% | -15.3% |
| 2014 | — | — | — | — | — | — | +50.0% | +0.0% | +0.0% | +19.3% | -16.2% | +3.3% |
| Avg | -6.3% | +2.9% | +8.0% | +15.4% | +10.1% | -12.7% | +5.5% | +1.6% | +15.4% | +4.1% | -1.0% | +4.4% |
| Median | -2.3% | -0.1% | +9.4% | +10.5% | -4.5% | -13.4% | +5.1% | -4.6% | +10.5% | -5.4% | -13.6% | +1.7% |
| Last 5Y Avg | -13.3% | +11.8% | +5.4% | +2.1% | +19.7% | -8.0% | +9.6% | +18.2% | +24.1% | -13.9% | +3.5% | +8.9% |
| Std Dev (σ) | 20.6% | 23.4% | 27.3% | 33.1% | 42.0% | 11.1% | 24.9% | 30.8% | 23.4% | 59.1% | 34.4% | 26.0% |
| Consistency (μ/σ) | -0.31 | 0.12 | 0.29 | 0.46 | 0.24 | -1.14 | 0.22 | 0.05 | 0.66 | 0.07 | -0.03 | 0.17 |
| Win Rate (%) | 42% | 50% | 75% | 75% | 33% | 18% | 58% | 33% | 75% | 42% | 25% | 50% |
| Winning / Losing Months | ▲5▼7 | ▲6▼6 | ▲9▼3 | ▲9▼3 | ▲4▼8 | ▲2▼9 | ▲7▼5 | ▲4▼8 | ▲9▼3 | ▲5▼7 | ▲3▼9 | ▲6▼6 |
| Longest Win / Loss Streak | ▲3▼3 | ▲3▼3 | ▲5▼2 | ▲6▼1 | ▲2▼4 | ▲1▼6 | ▲4▼3 | ▲2▼5 | ▲7▼2 | ▲2▼4 | ▲2▼5 | ▲1▼2 |
| Best | +19.6%in January 2019 | +55.7%in February 2024 | +52.6%in March 2026 | +89.0%in April 2016 | +132.6%in May 2025 | +2.5%in June 2015 | +50.0%in July 2014 | +79.9%in August 2025 | +79.5%in September 2025 | +173.2%in October 2019 | +99.6%in November 2025 | +66.8%in December 2023 |
| Worst | -44.5%in January 2016 | -32.5%in February 2017 | -37.2%in March 2023 | -29.5%in April 2015 | -25.1%in May 2022 | -26.5%in June 2018 | -36.0%in July 2015 | -31.2%in August 2016 | -11.2%in September 2023 | -78.4%in October 2022 | -27.5%in November 2022 | -31.1%in December 2024 |
−78.4%+173.2%
2026
Jan-26.5%
Feb+28.5%
Mar+52.6%
Apr+8.0%
May-4.1%
Jun-7.8%
Jul—
Aug—
Sep—
Oct—
Nov—
Dec—
2025
Jan-32.9%
Feb-25.5%
Mar+3.8%
Apr+19.4%
May+132.6%
Jun-20.0%
Jul+3.7%
Aug+79.9%
Sep+79.5%
Oct+12.4%
Nov+99.6%
Dec+7.1%
2024
Jan-4.6%
Feb+55.7%
Mar-24.2%
Apr-21.6%
May-17.6%
Jun+0.0%
Jul+22.0%
Aug-23.5%
Sep+15.7%
Oct+7.4%
Nov-13.2%
Dec-31.1%
2023
Jan+15.8%
Feb-10.9%
Mar-37.2%
Apr+11.5%
May+12.7%
Jun-13.4%
Jul+6.5%
Aug+29.0%
Sep-11.2%
Oct-0.3%
Nov-17.4%
Dec+66.8%
2022
Jan-18.4%
Feb+11.4%
Mar+31.7%
Apr-7.0%
May-25.1%
Jun+1.1%
Jul+34.7%
Aug+13.9%
Sep+26.9%
Oct-78.4%
Nov-27.5%
Dec-24.8%
2021
Jan+2.0%
Feb+2.0%
Mar+5.5%
Apr+9.5%
May-10.2%
Jun-7.5%
Jul-18.8%
Aug-8.1%
Sep+9.6%
Oct-10.5%
Nov-23.9%
Dec+26.3%
2020
Jan+13.7%
Feb+10.0%
Mar-30.1%
Apr+23.0%
May+14.9%
Jun-7.2%
Jul-18.8%
Aug-1.8%
Sep+5.3%
Oct-17.7%
Nov+14.9%
Dec-9.8%
2019
Jan+19.6%
Feb-3.6%
Mar+34.0%
Apr+2.1%
May+37.9%
Jun-26.0%
Jul+18.9%
Aug+15.9%
Sep+0.5%
Oct+173.2%
Nov+14.8%
Dec+21.3%
2018
Jan+0.0%
Feb-6.7%
Mar+27.1%
Apr+64.3%
May-6.0%
Jun-26.5%
Jul+18.8%
Aug-24.8%
Sep+24.1%
Oct+7.1%
Nov-3.3%
Dec-0.9%
2017
Jan+10.1%
Feb-32.5%
Mar+11.1%
Apr+15.6%
May-3.8%
Jun-18.0%
Jul+0.0%
Aug-7.3%
Sep+25.0%
Oct-15.5%
Nov-6.5%
Dec+0.0%
2016
Jan-44.5%
Feb+8.1%
Mar+13.3%
Apr+89.0%
May-5.8%
Jun-24.8%
Jul-15.4%
Aug-31.2%
Sep+11.3%
Oct-22.0%
Nov-13.9%
Dec+10.1%
2015
Jan-9.7%
Feb-2.1%
Mar+7.7%
Apr-29.5%
May-4.8%
Jun+2.5%
Jul-36.0%
Aug-23.1%
Sep-2.0%
Oct-25.5%
Nov-19.2%
Dec-15.3%
2014
Jan—
Feb—
Mar—
Apr—
May—
Jun—
Jul+50.0%
Aug+0.0%
Sep+0.0%
Oct+19.3%
Nov-16.2%
Dec+3.3%
Avg
Jan-6.3%
Feb+2.9%
Mar+8.0%
Apr+15.4%
May+10.1%
Jun-12.7%
Jul+5.5%
Aug+1.6%
Sep+15.4%
Oct+4.1%
Nov-1.0%
Dec+4.4%
Median
Jan-2.3%
Feb-0.1%
Mar+9.4%
Apr+10.5%
May-4.5%
Jun-13.4%
Jul+5.1%
Aug-4.6%
Sep+10.5%
Oct-5.4%
Nov-13.6%
Dec+1.7%
Last 5Y Avg
Jan-13.3%
Feb+11.8%
Mar+5.4%
Apr+2.1%
May+19.7%
Jun-8.0%
Jul+9.6%
Aug+18.2%
Sep+24.1%
Oct-13.9%
Nov+3.5%
Dec+8.9%
Std Dev (σ)
Jan20.6%
Feb23.4%
Mar27.3%
Apr33.1%
May42.0%
Jun11.1%
Jul24.9%
Aug30.8%
Sep23.4%
Oct59.1%
Nov34.4%
Dec26.0%
Consistency (μ/σ)
Jan-0.31
Feb0.12
Mar0.29
Apr0.46
May0.24
Jun-1.14
Jul0.22
Aug0.05
Sep0.66
Oct0.07
Nov-0.03
Dec0.17
Win Rate (%)
Jan42%
Feb50%
Mar75%
Apr75%
May33%
Jun18%
Jul58%
Aug33%
Sep75%
Oct42%
Nov25%
Dec50%
Winning / Losing Months
Jan▲5▼7
Feb▲6▼6
Mar▲9▼3
Apr▲9▼3
May▲4▼8
Jun▲2▼9
Jul▲7▼5
Aug▲4▼8
Sep▲9▼3
Oct▲5▼7
Nov▲3▼9
Dec▲6▼6
Longest Win / Loss Streak
Jan▲3▼3
Feb▲3▼3
Mar▲5▼2
Apr▲6▼1
May▲2▼4
Jun▲1▼6
Jul▲4▼3
Aug▲2▼5
Sep▲7▼2
Oct▲2▼4
Nov▲2▼5
Dec▲1▼2
Best
Jan+19.6%2019
Feb+55.7%2024
Mar+52.6%2026
Apr+89.0%2016
May+132.6%2025
Jun+2.5%2015
Jul+50.0%2014
Aug+79.9%2025
Sep+79.5%2025
Oct+173.2%2019
Nov+99.6%2025
Dec+66.8%2023
Worst
Jan-44.5%2016
Feb-32.5%2017
Mar-37.2%2023
Apr-29.5%2015
May-25.1%2022
Jun-26.5%2018
Jul-36.0%2015
Aug-31.2%2016
Sep-11.2%2023
Oct-78.4%2022
Nov-27.5%2022
Dec-31.1%2024
−78.4%+173.2%
Frequently asked questions
Data & methodology
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement